Defective hepatic conjugation is seen in all of the following conditions except?
What is the recommended treatment for latent tuberculosis infection in patients who are Tuberculin positive and HIV positive?
A 40-year-old female presents with koilonychias, iron deficiency, and dysphagia. What is the most likely diagnosis?
Which is the most likely cause of protein-losing enteropathy?
Secretory diarrhea is found in which of the following conditions?
Which of the following is NOT a feature of chronic liver disease?
Which of the following is a new drug available to treat multidrug-resistant tuberculosis?
Which of the following is an indicator of severe ulcerative colitis?
Which of the following is false regarding involvement in Crohn's disease?
A 40-year-old male patient presented with slowly progressive dysphagia to both solids and liquids, regurgitation, chest pain, and weight loss for 2 months. Investigations included barium swallow, esophageal manometry, and upper GI endoscopy. Which of the following organisms has been most commonly implicated in causing this condition?
Explanation: This question tests your knowledge of the mechanisms of unconjugated hyperbilirubinemia, specifically focusing on the enzyme **Uridine diphosphate-glucuronosyltransferase (UGT1A1)**. [1] ### **Explanation of the Correct Answer** **D. Novobiocin therapy:** While Novobiocin can cause unconjugated hyperbilirubinemia, it does so primarily by **inhibiting the hepatic uptake** of bilirubin, not by defecting the conjugation process itself. In NEET-PG, it is crucial to distinguish between defects in uptake (e.g., Rifampicin, Novobiocin) and defects in conjugation (e.g., Gilbert, Crigler-Najjar). [2] ### **Analysis of Incorrect Options** * **A. Neonatal jaundice:** This is a physiological state where conjugation is defective due to the **immaturity of the UGT1A1 enzyme** at birth, leading to transient unconjugated hyperbilirubinemia. [1] * **B. Gilbert syndrome:** This is a common hereditary condition characterized by **reduced activity (approx. 30%)** of UGT1A1, usually due to a promoter mutation (TATAA box). [1] * **C. Crigler-Najjar syndrome:** This involves a severe defect in conjugation. **Type I** has a total absence of UGT1A1 activity, while **Type II (Arias syndrome)** has a severe deficiency (<10% activity). [1] ### **High-Yield Clinical Pearls for NEET-PG** * **Gilbert Syndrome:** Most common hereditary hyperbilirubinemia; jaundice is triggered by fasting, stress, or infection. [1] * **Crigler-Najjar Type I:** Autosomal recessive; serum bilirubin >20 mg/dL; risk of kernicterus; does **not** respond to Phenobarbital. [1] * **Crigler-Najjar Type II:** Serum bilirubin <20 mg/dL; **responds** to Phenobarbital (induces enzyme activity). [1] * **Drug-induced uptake inhibition:** Rifampicin and Novobiocin are classic examples. [2]
Explanation: The management of Latent Tuberculosis Infection (LTBI) in HIV-positive individuals is critical due to their high risk of progression to active disease. **1. Why Option A is Correct:** According to the National AIDS Control Organization (NACO) and RNTCP guidelines, **Isoniazid Preventive Therapy (IPT)** is the standard of care for HIV-infected individuals who are Tuberculin Skin Test (TST) positive or have had contact with a TB case [1]. The recommended regimen is **Isoniazid (5 mg/kg/day)**. While daily administration is preferred in many global guidelines, for programmatic feasibility in certain settings (and as per specific NEET-PG patterns), **biweekly administration for 9 months** is a recognized strategy to ensure adherence and reduce the risk of reactivation [3]. **2. Why the Other Options are Incorrect:** * **Option B (2HRZ3 + 4HR3):** This is a multi-drug regimen used for treating **active** tuberculosis (Intensive and Continuation phases) [2]. Using this for latent TB would lead to unnecessary toxicity and potential drug resistance. * **Option C (Rifampicin biweekly for 6 months):** While Rifampicin can be used for LTBI (usually 4 months daily), it is not the primary recommendation for HIV patients due to significant drug-drug interactions with Protease Inhibitors and NNRTIs used in ART. * **Option D (Pyrazinamide daily for 6 months):** Pyrazinamide is never used as monotherapy for LTBI due to its high risk of hepatotoxicity and lack of efficacy as a single agent in latent stages. **3. High-Yield Clinical Pearls for NEET-PG:** * **TST Cut-off:** In HIV-positive patients, a TST (Mantoux) induration of **≥5 mm** is considered positive (unlike the ≥10 mm in immunocompetent individuals) [1]. * **Rule out Active TB:** Before starting IPT, active TB must be ruled out using a symptom screen (cough, fever, weight loss, night sweats) and chest X-ray [1]. * **Vitamin B6:** Always co-administer **Pyridoxine** with Isoniazid in HIV patients to prevent peripheral neuropathy [2]. * **Duration:** While 6 months is common, **9 months** of Isoniazid is considered the "gold standard" for maximum protective efficacy in HIV-positive patients.
Explanation: ### Explanation The correct answer is **Plummer-Vinson syndrome (PVS)**, also known as Paterson-Brown-Kelly syndrome. **1. Why Plummer-Vinson Syndrome is Correct:** PVS is characterized by a classic clinical triad: **Iron deficiency anemia (IDA), dysphagia, and esophageal webs.** * **Koilonychia:** This "spoon-shaped" nail deformity is a specific physical sign of chronic, severe iron deficiency. * **Dysphagia:** In PVS, this is typically painless and progressive, caused by the formation of post-cricoid esophageal webs (thin mucosal folds). * **Demographics:** It most commonly affects middle-aged women, matching the patient profile in the question. **2. Why Other Options are Incorrect:** * **Achalasia Cardia:** While it presents with dysphagia, it is a motility disorder due to the failure of the Lower Esophageal Sphincter (LES) to relax. It is not associated with iron deficiency or koilonychia. * **Zollinger-Ellison Syndrome:** This is caused by a gastrin-secreting tumor (gastrinoma) leading to severe peptic ulcers and diarrhea. It does not typically cause esophageal webs or koilonychia. **3. NEET-PG High-Yield Pearls:** * **Pre-malignant Condition:** PVS is a significant risk factor for **Squamous Cell Carcinoma** of the esophagus and pharynx. * **Diagnosis:** The investigation of choice for visualizing the web is a **Barium Swallow** (lateral view), though endoscopy is also used. * **Treatment:** The primary treatment is **Iron supplementation**, which often resolves the dysphagia. Refractory cases may require endoscopic dilation. * **Associated signs:** Glossitis (smooth red tongue) and cheilosis are also frequently seen in these patients.
Explanation: **Explanation:** **Protein-losing enteropathy (PLE)** refers to a condition where excessive amounts of serum proteins are lost into the gastrointestinal tract, leading to hypoproteinemia and edema [1, 3]. **Why Menetrier's Disease is the Correct Answer:** Menetrier’s disease is a classic and potent cause of PLE [1]. It is characterized by **massive hypertrophy of gastric rugal folds** due to excessive secretion of Transforming Growth Factor-alpha (TGF-α). This leads to: 1. **Mucosal hyperplasia:** Specifically of the surface mucous cells. 2. **Selective protein loss:** The enlarged folds and altered mucosal permeability allow massive leakage of albumin into the gastric lumen. 3. **Achlorhydria:** Due to the atrophy of parietal cells. **Analysis of Incorrect Options:** * **B. Monosaccharidase deficiency:** This is a malabsorption disorder (e.g., glucose-galactose malabsorption) leading to osmotic diarrhea, but it does not typically cause significant protein leakage. * **C. Sarcoidosis:** While sarcoidosis can involve the GI tract (granulomatous infiltration), it is a very rare cause of PLE compared to the primary mucosal pathology seen in Menetrier's. * **D. Celiac sprue:** While Celiac disease *can* cause PLE in severe cases due to villous atrophy, it is primarily a malabsorptive disorder [1]. Menetrier’s is more classically associated with profound protein loss as its hallmark feature. **NEET-PG High-Yield Pearls:** * **Diagnosis:** Menetrier’s is diagnosed via deep mucosal biopsy (showing "corkscrew" glands). * **Clinical Triad:** Large gastric folds, hypoproteinemia (edema), and low gastric acid. * **Association:** In children, it is often associated with **CMV infection** and is self-limiting; in adults, it is chronic and carries an increased risk of **gastric adenocarcinoma**. * **Other PLE causes:** Intestinal lymphangiectasia (most common cause of PLE in children), Crohn’s disease, and Constrictive pericarditis (due to high central venous pressure) [1, 4].
Explanation: **Explanation:** **Secretory diarrhea** occurs when there is an active secretion of electrolytes (primarily sodium and chloride) and water into the intestinal lumen, or an inhibition of their absorption. This process is independent of food intake and typically persists even during fasting. **Why Shigella is the correct answer:** *Shigella* species produce the **Shiga toxin** (and enterotoxins), which stimulates the mucosal cells to secrete fluids and electrolytes [2]. While *Shigella* is classically associated with inflammatory diarrhea (dysentery), its initial phase often presents as a profuse secretory diarrhea due to the action of enterotoxins on the small intestine before the organism invades the colonic mucosa [2]. **Analysis of Incorrect Options:** * **A. Thyrotoxicosis:** Causes diarrhea primarily through **hypermotility** (decreased transit time), which limits the time available for fluid absorption. * **C. Lactase deficiency:** Causes **osmotic diarrhea** [1]. Undigested lactose remains in the gut lumen, creating an osmotic gradient that pulls water into the intestine [1]. This diarrhea characteristically stops with fasting. * **D. Glucose intake:** In normal individuals, glucose aids sodium absorption via the SGLT-1 transporter. However, in cases of malabsorption, it acts as an **osmotic agent**, leading to osmotic diarrhea. **High-Yield Clinical Pearls for NEET-PG:** 1. **Stool Osmotic Gap:** In secretory diarrhea, the gap is **low (<50 mOsm/kg)**, whereas in osmotic diarrhea, it is **high (>125 mOsm/kg)**. 2. **Classic Example:** The "gold standard" for secretory diarrhea is **Vibrio cholerae** (via cAMP activation). 3. **Hormonal Causes:** VIPoma (Verner-Morrison syndrome), Carcinoid syndrome, and Medullary Thyroid Carcinoma are important non-infectious causes of secretory diarrhea.
Explanation: Chronic Liver Disease (CLD) is characterized by the progressive destruction of hepatic parenchyma, leading to fibrosis and cirrhosis [1]. **Why Koilonychia is the correct answer:** **Koilonychia** (spoon-shaped nails) is a classic sign of **Iron Deficiency Anemia**. While patients with CLD may develop anemia due to chronic blood loss (varices) or malnutrition [1], koilonychia is not a primary clinical feature or diagnostic sign of liver cirrhosis itself. In contrast, the characteristic nail finding in CLD is **Terry’s nails** (proximal 2/3rd white, distal 1/3rd red/pink) or clubbing [1]. **Analysis of incorrect options:** * **Hepatomegaly:** In the early stages of CLD (especially in alcoholic liver disease or NAFLD), the liver is often enlarged [1]. While the liver eventually shrinks and becomes nodular in advanced cirrhosis, hepatomegaly remains a recognized feature of the disease spectrum. * **Variceal Bleeding:** This is a direct consequence of **Portal Hypertension** [1]. Fibrosis increases intrahepatic resistance, diverting blood to portosystemic collaterals (esophageal/gastric varices), which are prone to rupture. * **Hepatic Encephalopathy:** This occurs due to the liver's inability to detoxify neurotoxic substances (like ammonia) and the shunting of blood around the liver, leading to altered mental status and asterixis [1]. **NEET-PG High-Yield Pearls:** * **Most common cause of CLD in India:** Post-hepatitic (Hepatitis B) followed by Alcohol. * **Stigmata of Hyperestrogenism in CLD:** Spider naevi (in the distribution of SVC), Palmar erythema, and Gynecomastia [1]. * **Cruveilhier-Baumgarten Murmur:** A venous hum heard over the epigastrium due to recanalization of the umbilical vein in portal hypertension. * **Child-Pugh Score parameters:** Bilirubin, Albumin, INR, Ascites, and Encephalopathy [1].
Explanation: Explanation: Bedaquiline (Option A) is the correct answer. It represents a breakthrough in the management of Multidrug-Resistant Tuberculosis (MDR-TB). It is a diarylquinoline that works by a unique mechanism: inhibiting the mycobacterial ATP synthase enzyme, thereby depleting the energy source of Mycobacterium tuberculosis. It was the first new class of TB drugs approved by the FDA in over 40 years and is a cornerstone of the WHO-recommended all-oral shorter regimens for MDR-TB. Analysis of Incorrect Options: * Rifampicin (Option B): This is a first-line antitubercular drug (Group 1). By definition, MDR-TB is characterized by resistance to at least Isoniazid and Rifampicin; therefore, it is not a "new" drug for treating MDR-TB, but rather the drug to which the bacteria are resistant [1]. * Linezolid (Option C): While Linezolid is used in the treatment of MDR-TB and XDR-TB (classified as a Group A drug by WHO), it is an oxazolidinone antibiotic originally developed for Gram-positive infections (like MRSA) [2]. It is not a "newly developed" drug specifically for TB in the same context as Bedaquiline. * Cefepime (Option D): This is a fourth-generation cephalosporin used for systemic bacterial infections (e.g., Pseudomonas). It has no clinical role in the treatment of tuberculosis. High-Yield Clinical Pearls for NEET-PG: * MDR-TB Definition: Resistance to at least Isoniazid (H) and Rifampicin (R). * Bedaquiline Side Effect: The most significant adverse effect is QT interval prolongation; baseline and follow-up ECGs are mandatory. * Pre-XDR TB: MDR-TB plus resistance to any fluoroquinolone. * XDR-TB: MDR-TB plus resistance to any fluoroquinolone AND at least one additional Group A drug (Bedaquiline or Linezolid). * Other New Drugs: Delamanid (inhibits mycolic acid synthesis) and Pretomanid are other recent additions to the MDR-TB armamentarium.
Explanation: The assessment of severity in Ulcerative Colitis (UC) is crucial for determining management strategies (outpatient vs. inpatient). [1] The correct answer is **Blood in lumen on sigmoidoscopy**, which is a key endoscopic marker of severe mucosal inflammation. [1] ### Why Option A is Correct According to the **Truelove and Witts criteria** and the **Mayo Score** (standard tools for UC assessment), endoscopic findings are pivotal. The presence of spontaneous bleeding or "blood in the lumen" indicates deep ulcerations and significant mucosal friability. In the Mayo Endoscopic Subscore, a score of 3 (Severe) is defined by spontaneous bleeding, prominent ulceration, and loss of vascular pattern. ### Why Other Options are Incorrect * **B. Stool volume > 1 liter:** While stool frequency (>6 times/day) is a criterion for severity, absolute stool volume is more characteristic of secretory diarrheas (like VIPoma or Cholera) rather than the inflammatory exudative diarrhea of UC. * **C. Serum albumin < 40 g/L:** While hypoalbuminemia is a marker of severity, the threshold in the Truelove and Witts criteria is typically **<30 g/L** (or <75% of normal). 40 g/L is within the low-normal range and is not specific for severe UC. * **D. Abdominal discomfort:** This is a subjective, non-specific symptom found in mild, moderate, and severe cases, as well as in Irritable Bowel Syndrome (IBS). ### NEET-PG High-Yield Pearls * **Truelove and Witts Criteria for Severe UC:** 1. Stools ≥6/day with macroscopic blood. [1] 2. Fever (>37.8°C). 3. Tachycardia (>90 bpm). 4. Anemia (Hb <75% of normal). 5. ESR >30 mm/hr. * **Toxic Megacolon:** A life-threatening complication of severe UC; diagnosed when the transverse colon diameter is **>6 cm** on X-ray. [1] * **Drug of Choice:** IV Corticosteroids (e.g., Hydrocortisone) are the first-line treatment for acute severe UC.
Explanation: In Crohn’s disease (CD), the **rectum is characteristically spared**, which is a key diagnostic feature distinguishing it from Ulcerative Colitis (UC) [1]. While UC always involves the rectum and spreads proximally, CD can affect any part of the gastrointestinal tract from the mouth to the anus in a non-contiguous ("skip lesions") fashion [1]. ### **Explanation of Options:** * **Option B (Rectum):** This is the correct answer because rectal involvement is rare in CD (seen in <20% of cases). The "rectal sparing" sign is a classic endoscopic finding used to differentiate CD from UC [1]. * **Option A (Anorectal area):** This is a common site for CD. Up to 30% of patients present with perianal complications such as fistulae, fissures, or perianal abscesses, even when the rectum itself is not inflamed [1]. * **Option C (Small intestine with right colon):** This is the most common presentation of CD (Ileocolic involvement), seen in approximately 40-50% of patients. The terminal ileum is the most frequently affected site [1]. * **Option D (Large intestine alone):** This occurs in about 20% of patients (Colonic Crohn’s). It can mimic UC but is distinguished by the presence of skip lesions and the absence of rectal involvement [1]. ### **High-Yield Clinical Pearls for NEET-PG:** * **Distribution:** CD is "transmural" (affects all layers) and "discontinuous" (skip lesions) [1]. * **Most Common Site:** Terminal ileum [1]. * **Microscopy:** Non-caseating granulomas (pathognomonic, but seen in only 50% of biopsies). * **Endoscopy:** "Cobblestone" appearance and "creeping fat" (mesenteric fat wrapping around the bowel). * **Serology:** ASCA (Anti-Saccharomyces cerevisiae antibodies) is positive in CD, whereas p-ANCA is associated with UC.
Explanation: ### **Explanation** **Diagnosis: Achalasia Cardia** The clinical presentation of progressive dysphagia to both solids and liquids, regurgitation, and weight loss, combined with the diagnostic workup (barium swallow and manometry), points toward **Achalasia Cardia**. This is a primary esophageal motility disorder characterized by the failure of the Lower Esophageal Sphincter (LES) to relax and the absence of esophageal peristalsis [1]. **1. Why HSV-1 is the Correct Answer:** The underlying pathophysiology of Achalasia involves the inflammatory destruction of inhibitory nitrergic neurons in the **myenteric (Auerbach’s) plexus** [1]. While the exact trigger is unknown, current research suggests an autoimmune response potentially triggered by a latent viral infection in genetically susceptible individuals. **Herpes Simplex Virus 1 (HSV-1)** is the organism most commonly implicated. Studies have identified HSV-1 DNA and antigens within the esophageal myenteric plexus of achalasia patients, suggesting that the virus may trigger a chronic T-cell-mediated immune response leading to neuronal loss. **2. Why Incorrect Options are Wrong:** * **HSV-2:** Primarily associated with genital herpes; it is not linked to the esophageal myenteric plexus. * **Varicella-Zoster Virus (VZV):** While neurotropic, it typically causes shingles or chickenpox and is not a recognized etiological factor for Achalasia. * **Cytomegalovirus (6CMV):** CMV usually causes erosive esophagitis in immunocompromised patients (e.g., HIV/AIDS) but does not cause the selective destruction of myenteric neurons seen in Achalasia. **3. High-Yield Clinical Pearls for NEET-PG:** * **Barium Swallow:** Shows the classic **"Bird’s Beak"** appearance (tapering at the LES) [1]. * **Manometry (Gold Standard):** Shows incomplete LES relaxation (IRP >15 mmHg) and aperistalsis [2]. * **Chagas Disease:** Caused by *Trypanosoma cruzi*, it is a common cause of **secondary achalasia** (Pseudoachalasia) in South America. * **Treatment:** Pneumatic dilation (most effective non-surgical), Heller’s Myotomy (surgical gold standard), or POEM (Per-Oral Endoscopic Myotomy).
Esophageal Disorders
Practice Questions
Peptic Ulcer Disease
Practice Questions
Inflammatory Bowel Disease
Practice Questions
Irritable Bowel Syndrome
Practice Questions
Malabsorption Syndromes
Practice Questions
Pancreatitis (Acute and Chronic)
Practice Questions
Gastrointestinal Bleeding
Practice Questions
Liver Diseases and Cirrhosis
Practice Questions
Viral Hepatitis
Practice Questions
Biliary Tract Disorders
Practice Questions
Gastrointestinal Motility Disorders
Practice Questions
Gastrointestinal Malignancies
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free